By interfering with macrophage migration, Kv1.3 inhibition could potentially disrupt the vicious cycle of inflammation and insulin resistance, offering a novel approach to managing MetS and preventing its progression to T2DM and its associated CV complications. Here, KCNA3 is linked to metabolic syndrome.